Antibody-Free Immunopeptide Nanoconjugates for Brain-Targeted Drug Delivery in Glioblastoma Multiforme

Area of Science:

• Nanomedicine
• Immunotherapy
• Neuro-oncology

Background:

• Glioblastoma Multiforme (GBM) has a poor prognosis due to treatment challenges, particularly the blood-brain barrier (BBB).
• Current immunotherapies struggle to reach brain tumors effectively.
• There is a critical need for novel therapeutic strategies to overcome the BBB and treat GBM.

Purpose of the Study:

• To develop and evaluate an actively targeted immunotherapeutic nanoconjugate (P-12/AP-2/NCs) capable of crossing the BBB.
• To assess the nanoconjugate's ability to inhibit the PD-1/PD-L1 immune checkpoint.
• To investigate the therapeutic potential of P-12/AP-2/NCs in glioblastoma models.

Main Methods:

• Synthesis of P-12/AP-2/NCs using biodegradable PMLA polymer conjugated with PD-1/PD-L1 antagonist peptide (P-12) and BBB-penetrating peptide (AP-2).
• In vitro evaluation of BBB permeability using a Transwell spheroid model and assessment of cytotoxicity in U87 GBM 3D spheroids.
• In vivo studies in murine models to assess brain accumulation, bioavailability, and safety via histopathology.

Main Results:

• P-12/AP-2/NCs successfully traversed the in vitro BBB model and were internalized into brain tumor spheroids.
• The nanoconjugate demonstrated T cell-mediated cytotoxicity against GBM spheroids.
• In vivo studies showed enhanced brain accumulation and prolonged bioavailability of AP-2/P-12/NCs post-injection.
• Histopathology confirmed a favorable safety profile for the nanoconjugates.

Conclusions:

• The developed P-12/AP-2/NCs represent a novel nanoconjugate platform for BBB penetration and targeted immunotherapy.
• This platform effectively modulates the tumor immune microenvironment by inhibiting the PD-1/PD-L1 axis.
• The findings offer a promising strategy for treating glioblastoma and other challenging brain diseases.